Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, pharmacokinetics, and efficacy of lenabasum (JBT-101) in cystic fibrosis; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• JBT-101 (Lenabasum) (lenabasum)

Snippet

Sponsor: Corbus Pharmaceuticals Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2018-02-09